March 9, 2025
ORLANDO, Fla. — A novel topical therapy for axial hyperhidrosis approved by the FDA in June 2024 is among the increasing number of therapeutic options and […]
March 9, 2025
Edited By Deepa Varma TOPLINE: Children are at increased risk for atopic dermatitis (AD) after exposure to fine particulate matter (PM2.5) during late pregnancy and early […]
March 9, 2025
Mar 07 2025 This Week in Cardiology Commentary March 7, 2025 Listener feedback on asymptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) vs […]
March 7, 2025
A chemical compound used in many permanent hair dyes has been named Allergen of the Year for 2025 by the American Contact Dermatitis Society (ACDS). Toluene-2,5-diamine […]
March 7, 2025
TOPLINE: Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduced itch and hives in patients with chronic spontaneous urticaria and showed a favorable safety profile at week […]
March 7, 2025
TOPLINE: A low-dose (40 mg) modified formulation of minocycline hydrochloride (DFD-29) was better tolerated and more effective than doxycycline and placebo in patients with moderate to […]
March 6, 2025
In a recent case report, a novel immunophenotyping platform featuring high-parameter flow cytometry of peripheral blood mononuclear cells (PBMCs) enabled physicians to discover a unique skin […]
March 6, 2025
TOPLINE: Upadacitinib, a Janus kinase 1 inhibitor, demonstrated comparable safety and effectiveness over 2 years in patients with moderate to severe atopic dermatitis (AD), regardless of […]
March 5, 2025
TOPLINE: At-home light-emitting diode (LED) devices using red and/or blue light significantly reduced acne lesions and showed a favorable safety profile in patients with mild to […]